Trial Profile
A Phase II Study of Pembrolizumab and Eribulin in Patients With HR-positive/HER2-negative Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 15 Jun 2022
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms KELLY
- Sponsors Medica Scientia Innovation Research
- 29 Mar 2021 Results published in the European Journal of Cancer
- 03 Mar 2021 Status changed from active, no longer recruiting to completed.
- 23 Nov 2020 Planned End Date changed from 31 Oct 2020 to 31 Dec 2020.